Overview

Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases

Status:
Completed

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of the conditioning) of the busulfan, in preparation for a allogenic transplant family or not family compatible HLA.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Paoli-Calmettes

Collaborator:

Agence de La Biomédecine

Treatments:

Busulfan
Fludarabine
Thymoglobulin